IL100663A - Medicinal preparations containing salts of A-) S-adenosylmethionine (-O-tocopherol for the prevention of scabies of sickle cells - Google Patents

Medicinal preparations containing salts of A-) S-adenosylmethionine (-O-tocopherol for the prevention of scabies of sickle cells

Info

Publication number
IL100663A
IL100663A IL10066392A IL10066392A IL100663A IL 100663 A IL100663 A IL 100663A IL 10066392 A IL10066392 A IL 10066392A IL 10066392 A IL10066392 A IL 10066392A IL 100663 A IL100663 A IL 100663A
Authority
IL
Israel
Prior art keywords
group
pharmaceutical composition
agents
sickling
sickle cell
Prior art date
Application number
IL10066392A
Other languages
English (en)
Hebrew (he)
Other versions
IL100663A0 (en
Original Assignee
Michael Wilburn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Wilburn filed Critical Michael Wilburn
Publication of IL100663A0 publication Critical patent/IL100663A0/xx
Publication of IL100663A publication Critical patent/IL100663A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL10066392A 1991-02-08 1992-01-15 Medicinal preparations containing salts of A-) S-adenosylmethionine (-O-tocopherol for the prevention of scabies of sickle cells IL100663A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/652,773 US5108754A (en) 1991-02-08 1991-02-08 Orthomolecular method of treating sickle cell disease

Publications (2)

Publication Number Publication Date
IL100663A0 IL100663A0 (en) 1992-09-06
IL100663A true IL100663A (en) 1995-10-31

Family

ID=24618098

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10066392A IL100663A (en) 1991-02-08 1992-01-15 Medicinal preparations containing salts of A-) S-adenosylmethionine (-O-tocopherol for the prevention of scabies of sickle cells

Country Status (15)

Country Link
US (1) US5108754A (ja)
EP (1) EP0571474B1 (ja)
JP (1) JPH06507382A (ja)
KR (1) KR100221118B1 (ja)
AP (1) AP275A (ja)
AT (1) ATE175204T1 (ja)
AU (1) AU662124B2 (ja)
BR (1) BR9205609A (ja)
CA (1) CA2103580C (ja)
DE (1) DE69228054T2 (ja)
DK (1) DK0571474T3 (ja)
ES (1) ES2125887T3 (ja)
GR (1) GR3029742T3 (ja)
IL (1) IL100663A (ja)
WO (1) WO1992013522A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
HUT72422A (en) * 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
KR20020088498A (ko) * 2001-05-17 2002-11-29 (주)미토콘 에스-아데노실메티오닌을 유효성분으로 함유하는 인슐린저항증 개선용 조성물
DE10243234A1 (de) * 2002-09-17 2004-03-25 Phenion Gmbh & Co. Kg Tocopherylester
DE602004008927T2 (de) * 2003-07-09 2008-06-05 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
AU2008345034A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
CA2956715C (en) * 2014-07-30 2024-01-02 Case Western Reserve University Biochips to diagnose hemoglobin disorders and monitor blood cells
CA2963819A1 (en) * 2014-10-08 2016-04-14 Epigenetics Pharma Llc Vitamin e-nucleoside prodrugs
WO2016196281A1 (en) * 2015-06-01 2016-12-08 Nanometics Llc Mtap inhibitors for the treatment of sickle cemtap disease
KR102291911B1 (ko) 2016-09-08 2021-08-23 헤멕스 헬스, 인크. 진단 시스템 및 방법
US10349589B2 (en) 2016-09-08 2019-07-16 Hemex Health, Inc. Diagnostics systems and methods
KR20190092778A (ko) 2018-01-31 2019-08-08 양원용 태양광을 이용한 기능성 전동식 농약분무기
WO2020264182A1 (en) 2019-06-25 2020-12-30 Hemex Health, Inc. Diagnostics systems and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57609A (en) * 1979-06-21 1983-05-15 Yeda Res & Dev Pharmaceutical compositions for the treatment of sickle cell disease comprising p-nitrobenzyl esters or amides of aromatic or hydrophobic aminoacids
US4612194A (en) * 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease

Also Published As

Publication number Publication date
DK0571474T3 (da) 1999-08-30
AU1250592A (en) 1992-09-07
CA2103580C (en) 2002-11-26
US5108754A (en) 1992-04-28
WO1992013522A1 (en) 1992-08-20
AP9200358A0 (en) 1992-04-30
AP275A (en) 1993-07-18
ES2125887T3 (es) 1999-03-16
KR100221118B1 (ko) 1999-09-15
EP0571474A1 (en) 1993-12-01
EP0571474A4 (ja) 1994-02-09
BR9205609A (pt) 1994-07-26
JPH06507382A (ja) 1994-08-25
GR3029742T3 (en) 1999-06-30
EP0571474B1 (en) 1998-12-30
DE69228054D1 (de) 1999-02-11
IL100663A0 (en) 1992-09-06
ATE175204T1 (de) 1999-01-15
CA2103580A1 (en) 1992-08-09
DE69228054T2 (de) 1999-08-05
AU662124B2 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
US5108754A (en) Orthomolecular method of treating sickle cell disease
Hanley et al. Hyperserotonemia and amine metabolites in autistic and retarded children
Abraham et al. Vanillin, a potential agent for the treatment of sickle cell anemia
Nagel et al. The paradox of hemoglobin SC disease
ZUELZER et al. Acute hemolytic anemia due to naphthalene poisoning: a clinical and experimental study
Rieder et al. Hemoglobin Zürich: clinical, chemical and kinetic studies
Grinstein et al. Hemoglobin metabolism in thalassemia: in vivo studies
Wranne Transient erythroblastopenia in infancy and childhood
McCurdy Chloramphenicol bone marrow toxicity
Bank et al. Absolute rates of globin chain synthesis in thalassemia
Koup et al. Chloramphenicol pharmacokinetics in hospitalized patients
Harig et al. D-glucose and L-leucine transport by human intestinal brush-border membrane vesicles
US5177208A (en) Orthomolecular method of treating sickle cell disease
Parfitt Familial neonatal hypoproteinaemia with exudative enteropathy and intestinal lymphangiectasis.
Eshaghpour et al. The relationship of erythrocyte glucose-6-phosphate dehydrogenase deficiency to hyperbilirubinemia in Negro premature infants
Walt et al. Erythroid hypoplasia in kwashiorkor
Charache et al. Hemoglobin SC, SS/GPhiladelphia and SOArab diseases: Diagnostic importance of an integrative analysis of clinical, hematologic and electrophoretic findings
Janakiraman et al. Hemolysis during BAL chelation therapy for high blood lead levels in two G6PD deficient children
Tubergen et al. Hereditary orotic aciduria with normal growth and development
Mengel et al. Development of hemolytic anemia in rats fed methionine
Kim et al. Inclusions in red blood cells containing Hb S or Hb C
Melikian et al. Bioavailability of potassium from three dosage forms: suspension, capsule, and solution
Smith Anemias in infancy and childhood: diagnostic and therapeutic considerations
Yeager et al. Hemoglobin Cheverly: an unstable hemoglobin associated with chronic mild anemia
Boelaert et al. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees